Eversept Partners’s AC Immune ACIU Stock Holding History

Eversept Partners’s Portfolio ACIU Stock Details ACIU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-100,752	Closed	-$205K	–	87
2025 Q2	$205K	Hold	100,752	–	–	0.02%	68
2025 Q1	$188K	Buy	+100,752	New	+$254K	0.02%	57
2024 Q4	–	Sell	-99,313	Closed	-$375K	–	66
2024 Q3	$375K	Hold	99,313	–	–	0.03%	67
2024 Q2	$396K	Sell	99,313 -25,276	-20%	-$83.6K	0.03%	73
2024 Q1	$369K	Hold	124,589	–	–	0.02%	70
2023 Q4	$623K	Hold	124,589	–	–	0.05%	57
2023 Q3	$355K	Hold	124,589	–	–	0.03%	69
2023 Q2	$368K	Hold	124,589	–	–	0.03%	68
2023 Q1	$292K	Hold	124,589	–	–	0.02%	62
2022 Q4	$254K	Hold	124,589	–	–	0.02%	64
2022 Q3	$394K	Hold	124,589	–	–	0.03%	64
2022 Q2	$450K	Hold	124,589	–	–	0.03%	73
2022 Q1	$498K	Sell	124,589 -28,791	-19%	-$125K	0.04%	75
2021 Q4	$759K	Sell	153,380 -68,369	-31%	-$397K	0.05%	93
2021 Q3	$1.49M	Buy	+221,749	New	+$1.59M	0.1%	85

Other funds holding ACIU

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Eversept Partners's ACIU Position: Q3 2025 in Review

Eversept Partners sold out of AC Immune (ACIU) in Q3 2025, closing a stake of 100,752 shares — an estimated $205K sold.

Eversept Partners first reported a position in ACIU in Q3 2021 and held it in 15 quarters. The position peaked at $1.49M in Q3 2021. 40 funds tracked by Wall St. Rank hold ACIU as of Q3 2025.

Eversept Partners reported no remaining AC Immune position as of Q3 2025 after selling out during the quarter.
Eversept Partners sold 100,752 AC Immune shares in Q3 2025, an estimated $205K.
Eversept Partners first reported a position in AC Immune in Q3 2021 and held it in 15 quarters.
Eversept Partners's AC Immune position peaked at $1.49M in Q3 2021.
40 funds tracked by Wall St. Rank held AC Immune as of Q3 2025.

Based on Eversept Partners's 13F filing for Q3 2025, filed 14 Nov 2025.